Tilray Announces Bulk Medical Cannabis Oil Import into the UK

Tilray (NASDAQ: TLRY) announced early this morning the successful importation of a bulk medical cannabis oil shipment into the United Kingdom. The medical cannabis oral solution was shipped from its GMP certified facility in Canada. The shipment by Tilray will allow the company to provide UK medical patients with a local supply of high-quality cannabis oil.

Back in September of 2018, Tilray reported the successful delivery and importation of Tilray 2:100 medical cannabis oil. This shipment was important because it was specifically for a pediatric patient in the United Kingdom in need of medicinal cannabis oil.

The 2:100 cannabis oil Tilray supplied was done through a government-approved special access program following a historic announcement made by the UK Home Secretary. The announcement allowed for patients with an exceptional medical need to legally obtain a prescription for cannabis-derived medicine.

Source: Shutterstock

“As demand ramps up in the U.K., Tilray is well positioned to be a leading supplier of medical cannabis products,” says Sascha Mielcarek, Managing Director of Tilray Europe. “Regulations are progressing as more and more countries across Europe are recognizing the benefits of medical cannabis and its potential to improve patients’ quality of life. We’re pleased to reaffirm our commitment to delivering medical cannabis to patients in the U.K. and look forward to offering a variety of GMP-certified, pharmaceutical-grade products in the coming months.”

There are now 6 medical cannabis products by Tilray that are approved for medicinal use in the United Kingdom. These 6 products can be obtained legally by patients with a medical cannabis prescription by either the National Health Service or through a private practice. Tilray expects to be in a position to supply UK patients with a variety of CBD, THC and balanced CBD/THC medical cannabis oils.

“This bulk import of Tilray medical cannabis oral solutions provides patients in need access to a sustained supply of GMP-certified, high-quality medical cannabis,” says Catherine Jacobson, Tilray’s Vice President of Medical and Regulatory Affairs. “This is an important step in improving access in the U.K. Tilray will continue to advocate for reasonable patient access to medical cannabis in the U.K. and countries around the world.”

Investors looking for additional information on Tilray are encouraged to visit the company’s website here.

Additional investor due diligence links: Tilray IR Website & Tilray Investor Deck

Stay up to date with all things Tilray by following them on social media: Facebook, Twitter, and Instagram

About Tilray:

Tilray is a global pioneer in the research, cultivation, production, and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in 12 countries spanning five continents.

Read full Tilray press release